The North America Tissue Diagnostics Market is expected to reach $2.96 billion by 2030, at a CAGR of 7% during the forecast period 2023–2030. Tissue diagnostics involves the study of tissue to diagnose disease and determine the type of the tissue, whether it's cancerous, and the characteristics of observed cancer. It uses instruments such as slide staining systems, slide scanners, tissue processing systems, embedding systems, and tissue microarrays.
The increasing prevalence of cancer, rising healthcare expenditure, advanced infrastructure for cancer diagnosis, recommendations/guidelines and programs for cancer screening and government initiatives for cancer research are the key factors driving the tissue diagnostics market in North America. In addition, the inclination towards personalized healthcare, growing awareness regarding early disease diagnosis, and adoption of digital pathology & automation in tissue diagnostics are expected to offer significant growth opportunities in the market.
According to the American Cancer Society, cancer is a leading cause of death, accounting for around 608,570 deaths in the U.S. in 2021. Prostate, lung, and colorectal cancers are common in men and breast and colorectal cancers in women. Cancer incidence is increasing due to unhealthy diets, tobacco use, alcohol consumption, sedentary lifestyles, carcinogen exposure, obesity, and pollution. Early detection is critical in reducing mortality, improving the chances of survival, and saving on treatment costs. The burden of cancer is growing in North America due to the growing population, changing lifestyles, people living longer and others.
Lung cancer is the second most common cancer in men and women. According to the GLOBOCAN, in 2020, it is estimated that around 253,537 new lung cancer cases were diagnosed, and it is expected to reach up to 352,415 by 2040. Most older adults are diagnosed with cancer due to declining bodily functions and immunity. The people diagnosed with lung cancer are usually 65 years and above.
Early diagnosis and the exact nature of the tumor detected are important in cancer diagnostics. Early cancer detection and access to effective anti-cancer treatments can improve patients’ survival rates and quality of life. Thus, the overall scenario indicates that the rising prevalence of cancer is expected to boost the demand for tissue diagnostics in North America, driving the market.
Click here to: Get a Free Sample Copy of this Report
Screening tests are used to detect cancer before a person has any symptoms. Cancer screening programs aim to reduce mortality and morbidity through early detection and treatment. The American Cancer Society's (ACS) recommendations & guidelines for screening certain cancers are useful for early detection. In 2021, the American Cancer Society launched the ‘Get Screened’ campaign to encourage people to schedule regular cancer screening tests. Although the COVID-19 pandemic resulted in cancer screening procedures being put on hold, the American Cancer Society's Get Screened initiative aimed to increase cancer screening rates by raising awareness about the importance of recommended screenings. In June 2021, PatientPoint, a patient engagement platform, launched a point-of-care campaign to promote the ACS Get Screened initiative. This point-of-care campaign highlighted the importance of routine cancer screening across nearly 100,000 healthcare providers in more than 25,000 offices in the country.
Key Findings of North America Tissue Diagnostics Market Study:
The Consumables Segment is Expected to Dominate the North America Tissue Diagnostics Market in 2023
Among the product types, in 2023, the consumables segment is expected to account for the largest share of the market. Factors such as the recurring requirement for consumables and research in developing novel reagents, the frequent use of antibodies, assays & kits in the detection of various infectious diseases, commercial availability of a diverse range of reagents, and increasing demand for COVID-19 testing products are driving the growth of this segment.
The Immunohistochemistry (IHC) Segment is Expected to Dominate the North America Tissue Diagnostics Market in 2023
Among the techniques, in 2023, the immunohistochemistry (IHC) segment is expected to account for the largest share of the market. This segment’s large share is mainly attributed to the high cancer screening rate, technological advancements in IHC, and the availability of reimbursement policies for IHC-based tests. Immunohistochemistry provides variations between different types of tumors; hence it is preferred over conventional enzyme staining techniques, especially in cancer screening.
Based on Application, the Breast Cancer Segment is Expected to Dominate the North America Tissue Diagnostics Market in 2023
Among the applications, in 2023, the breast cancer segment is expected to account for the largest share of the market. The large market share of this segment is mainly attributed to the high incidence rate of breast cancer. Breast cancer is the most prevalent cancer in the world. In 2020, there were 281,591 women diagnosed with breast cancer. The incidence of breast cancer is estimated to reach 316,632 cases by 2030 in the region. (Source: International Agency for Research on Cancer)
In 2023, the Hospitals & Diagnostic Laboratories Segment is Expected to Account for the Largest Share of the North America Tissue Diagnostics Market
Among the end users, in 2023, the hospitals & diagnostics laboratories segment is expected to account for the largest share of the North America tissue diagnostics market. The large market share of this segment is attributed to the high cancer incidence rate, the aging population, the availability of several cancer screening programs, and awareness regarding cancer diagnostics. Hospitals & diagnostic laboratories are the first point of contact for diagnosing or treating diseases. These laboratories perform various tests to help diagnose diseases and ensure the appropriate clinical treatment and prevention planning. They are also adopting advanced technologies to boost cancer diagnosis.
U.S.: Fastest Growing Market
The U.S. is expected to account for the largest share of the North America tissue diagnostics market in 2023. The large market share of the segment is attributed to the high geriatric population coupled with the growing number of cancer cases, government funding and initiatives to promote cancer screenings and the presence of key players in the region.
Key Players
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by leading market players in the industry over the years. The key players profiled in the North America tissue diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (U.S.), Abcam plc (U.K.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), BIO SB Inc.(U.S.), Bio-Genex Laboratories (U.S.), HOLOGIC, INC. (U.S.), and Sakura Finetek Japan Co., Ltd. (Japan).
Scope of the Report:
North America Tissue Diagnostics Market Assessment, by Product Type
North America Tissue Diagnostics Market Assessment, by Technique
North America Tissue Diagnostics Market Assessment, by Application
North America Tissue Diagnostics Market Assessment, by End User
North America Tissue Diagnostics Market Assessment, by Country
Key questions answered in the report:
The North America tissue diagnostics market covers consumables and Instruments for breast, lung, colorectal & gastrointestinal cancer, prostate cancer, lymphoma, and other applications.
The North America tissue diagnostics market is projected to reach $2.96 billion by 2030, at a CAGR of 7% during the forecast period.
The consumables segment is expected to account for the largest North America tissue diagnostics market share in 2023. The large share of the segment is attributed to the factors such as recurring requirements for consumables and research in developing novel reagents and other consumables, wide availability of ready-to-use reagents to eliminate the risk of tissue damages, and several launches of antibodies due to high demand for cancer research.
Based on the technique, the immunohistochemistry (IHC) segment is projected to create more traction over the forecast period.
Based on application, the breast cancer segment is projected to expected to account for the largest share of the North America tissue diagnostics market in 2023 due to the increasing prevalence of breast cancer, the large number of screening programs and the increasing government initiatives & private organizations to improve awareness about breast cancer.
The growing number of cancer cases, rising healthcare expenditure, advanced infrastructure for cancer diagnosis, recommendations/guidelines and programs for cancer screening and government initiatives for cancer research are the key factors driving the growth of the tissue diagnostics market in North America. In addition, the inclination towards personalized healthcare, growing awareness regarding early disease diagnosis, and adoption of digital pathology & automation in tissue diagnostics are expected to offer significant growth opportunities in the market.
The key players profiled in the North America tissue diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (U.S.), Abcam plc (U.K.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), BIO SB Inc.(U.S.), Bio-Genex Laboratories (U.S.), HOLOGIC, INC. (U.S.), and Sakura Finetek Japan Co., Ltd. (Japan).
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for this Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Cancer Cases
4.2.2. Government Initiatives for Cancer Research
4.2.3. Rising Healthcare Expenditure
4.2.4. Advanced Infrastructure for Cancer Diagnosis
4.2.5. Recommendations/Guidelines and Programs for Cancer Screening
4.3. Restraints
4.3.1. Product Issues & Recalls
4.3.2. Stringent Technical Requirements
4.4. Opportunities
4.4.1. Inclination Toward Personalized Medicine
4.4.2. Adoption of Digital Pathology & Automation in Tissue Diagnostics
4.5. Challenges
4.5.1. Shortage of Histopathologists
4.6. Regulatory Analysis
4.7. Pricing Analysis
4.8. Porter’s Five Forces Analysis
5. North America Tissue Diagnostics Market Assessment—by Product Type
5.1. Overview
5.2. Consumables
5.2.1. Kits & reagents
5.2.2. Antibodies
5.4. Instruments
5.4.1. Slide Staining Systems
5.4.2. Tissue Microarrays
5.4.3. Slide Scanners
5.4.4. Tissue Processors
5.4.5. Other Instruments
6. North America Tissue Diagnostics Market Assessment—by Technique
6.1. Overview
6.2. Immunohistochemistry (IHC)
6.3. In-situ hybridization (ISH)
6.4. Digital Pathology
6.5. H&E and Special Staining
6.6. Molecular Diagnostics
6.7. Other Techniques
7. North America Tissue Diagnostics Market Assessment—by Application
7.1. Overview
7.2. Breast Cancer
7.3. Lung Cancer
7.4. Colorectal & Gastrointestinal Cancer
7.5. Prostate Cancer
7.6. Lymphoma
7.7. Other Applications
8. North America Tissue Diagnostics Market Assessment—by End User
8.1. Introduction
8.2. Diagnostic Laboratories
8.3. Hospitals & Clinics
8.4. Home Healthcare
8.5. Other End Users
9. North America Tissue Diagnostics Market Assessment—by Geography
9.1. Overview
9.2. U.S.
9.3. Canada
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Vendor Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis/ Market Rankings (2022)
11. Company Profiles (Business Overview, Financial Overview, SWOT Analysis of the Top 5 Companies, Product Portfolio, Strategic Developments)
11.1. F. Hoffmann-La Roche Ltd.
11.2. Thermo Fisher Scientific Inc.
11.3. Abbott Laboratories
11.4. Danaher Corporation
11.5. QIAGEN N.V.
11.6. Becton, Dickinson and Company
11.7. Abcam plc
11.8. Agilent Technologies, Inc.
11.9. Merck KGaA
11.10. Cell Signaling Technology, Inc.
11.11. BIO SB Inc.
11.12. Bio-Genex Laboratories
11.13. HOLOGIC, INC.
11.14. Sakura Finetek Japan Co., Ltd.
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 North America Tissue Diagnostics Market, by Product Type, 2021–2030 (USD million)
Table 2 North America Tissue Diagnostics Consumables Market, by Type, 2021–2030 (USD million)
Table 3 North America Tissue Diagnostics Consumables Market, by Country, 2021–2030 (USD million)
Table 4 North America Tissue Diagnostics Antibodies Market, by Country, 2021–2030 (USD million)
Table 5 North America Tissue Diagnostics Kits & Reagents Market, by Country, 2021–2030 (USD million)
Table 6 North America Tissue Diagnostics Instruments Market, by Type, 2021–2030 (USD million)
Table 7 North America Instruments for Tissue Diagnostics Market, by Country, 2021–2030 (USD million)
Table 8 North America Slide Staining Systems for Tissue Diagnostics Market, by Country, 2021–2030 (USD million)
Table 9 North America Slide Scanners for Tissue Diagnostics Market, by Country, 2021–2030 (USD million)
Table 10 North America Tissue Processors for Tissue Diagnostics Market, by Country, 2021–2030 (USD million)
Table 11 North America Tissue Microarrays for Tissue Diagnostics Market, by Country, 2021–2030 (USD million)
Table 12 North America Other Instruments for Tissue Diagnostics Market, by Country, 2021–2030 (USD million)
Table 13 North America Tissue Diagnostics Market, by Technique, 2021–2030 (USD million)
Table 14 North America Tissue Diagnostics Market for Immunohistochemistry, by Country, 2021–2030 (USD million)
Table 15 North America Tissue Diagnostics Market for In-Situ Hybridization, by Country, 2021–2030 (USD million)
Table 16 North America Tissue Diagnostics Market for Digital Pathology, by Country, 2021–2030 (USD million)
Table 17 North America Tissue Diagnostics Market for H&E And Special Staining, by Country, 2021–2030 (USD million)
Table 18 North America Tissue Diagnostics Market for Molecular Diagnostics, by Country, 2021–2030 (USD million)
Table 19 North America Tissue Diagnostics Market for Other Techniques, by Country, 2021–2030 (USD million)
Table 20 North America Tissue Diagnostics Market, by Application, 2021–2030 (USD million)
Table 21 North America Tissue Diagnostics Market For Breast Cancer, by Country, 2021–2030 (USD million)
Table 22 North America Tissue Diagnostics Market For Lung Cancer, by Country, 2021–2030 (USD million)
Table 23 North America Tissue Diagnostics Market For Colorectal & Gastrointestinal Cancer, by Country, 2021–2030 (USD million)
Table 24 North America Tissue Diagnostics Market For Prostate Cancer, by Country, 2021–2030 (USD million)
Table 25 North America Tissue Diagnostics Market For Lymphatic Cancer, by Country, 2021–2030 (USD million)
Table 26 North America Tissue Diagnostics Market For Other Applications, by Country, 2021–2030 (USD million)
Table 27 North America Tissue Diagnostics Market, by End User, 2021–2030 (USD million)
Table 28 North America Tissue Diagnostics Market for Hospitals & Diagnostic Laboratories, by Country, 2021–2030 (USD million)
Table 29 North America Tissue Diagnostics Market for Research Institutes, by Country, 2021–2030 (USD million)
Table 30 North America Tissue Diagnostics Market for Pharmaceutical Companies, by Country/Region, 2021–2030 (USD million)
Table 31 North America Tissue Diagnostics Market for Contract Research Organization, by Country, 2021–2030 (USD million)
Table 32 North America: Tissue Diagnostics Market, by Country, 2021–2030 (USD million)
Table 33 North America: Tissue Diagnostics Market, by Product Type, 2021–2030 (USD million)
Table 34 North America: Tissue Diagnostics Consumables Market Size, by Type, 2021–2030 (USD million)
Table 35 North America: Tissue Diagnostics Instruments Market, by Type, 2021–2030 (USD million)
Table 36 North America: Tissue Diagnostic Market, by Technique, 2021–2030 (USD million)
Table 37 North America: Tissue Diagnostics Market, by Application, 2021–2030 (USD million)
Table 38 North America: Tissue Diagnostics Market, by End User, 2021–2030 (USD million)
Table 39 U.S.: Tissue Diagnostics Market Size, by Product Type, 2021–2030 (USD million)
Table 40 U.S.: Tissue Diagnostics Consumables Market, by Type, 2021–2030 (USD million)
Table 41 U.S.: Tissue Diagnostics Instruments Market, by Type, 2021–2030 (USD million)
Table 42 U.S.: Tissue Diagnostics Market, by Technique, 2021–2030 (USD million)
Table 43 U.S.: Tissue Diagnostics Market, by Application, 2021–2030 (USD million)
Table 44 U.S.: Tissue Diagnostics Market, by End User, 2021–2030 (USD million)
Table 45 Canada: Tissue Diagnostics Market, by Product Type, 2021–2030 (USD million)
Table 46 Canada: Tissue Diagnostics Consumables Market by Type, 2021–2030 (USD million)
Table 47 Canada: Tissue Diagnostics Instruments Market, by Type, 2021–2030 (USD million)
Table 48 Canada: Tissue Diagnostic Market, by Technique, 2021–2030 (USD million)
Table 49 Canada.: Tissue Diagnostics Market, by Application, 2021–2030 (USD million)
Table 50 Canada: Tissue Diagnostics Market, by End User, 2021–2030 (USD million)
Table 51 Recent Developments, by Company, 2020—2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Size Estimation
Figure 7 North America Tissue Diagnostics Market, by Product Type, 2023–2030 (USD Million)
Figure 8 North America Tissue Diagnostics Market, by Technique, 2023–2030 (USD Million)
Figure 9 North America Tissue Diagnostics Market, by Application, 2023–2030 (USD Million)
Figure 10 North America Tissue Diagnostics Market, by End User, 2023–2030 (USD Million)
Figure 11 North America Tissue Diagnostics Market, by Country, 2023 VS. 2030 (USD Million)
Figure 12 Impact Analysis: North America Tissue Diagnostics Market
Figure 13 Market Dynamics: North America Tissue Diagnostics Market
Figure 14 North America Tissue Diagnostics Market Size, by Product Type, 2023 VS. 2030 (USD Million)
Figure 15 North America Tissue Diagnostics Market Size, by Technique, 2023 VS. 2030 (USD Million)
Figure 16 North America Tissue Diagnostics Market Size, by Application, 2023 VS. 2030 (USD Million)
Figure 17 North America Tissue Diagnostics Market Size, by End User, 2023 VS. 2030 (USD Million)
Figure 18 North America Tissue Diagnostics Market, by Country, 2023 VS. 2030 (USD Million)
Figure 19 North America Tissue Diagnostics Market Snapshot
Figure 20 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 21 North America Tissue Diagnostics Market: Vendor Dashboard
Figure 22 North America Tissue Diagnostics Market: Competitive Benchmarking, by Type
Figure 23 F. Hoffman-La Roche Ltd.: Financial Overview (2022)
Figure 24 Thermo Fisher Scientific Inc.: Financial Overview (2022)
Figure 25 Abbott Laboratories: Financial Overview (2022)
Figure 26 Danaher Corporation: Financial Overview (2022)
Figure 27 Qiagen N.V.: Financial Overview (2022)
Figure 28 Becton, Dickinson, And Company: Financial Overview (2022)
Figure 29 Abcam Plc: Financial Overview (2022)
Figure 30 Agilent Technologies, Inc.: Financial Overview (2022)
Figure 31 Merck KGaA: Financial Overview (2022)
Figure 32 Hologic Inc.: Financial Overview (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Sep-2023
Published Date: Aug-2023
Published Date: Jul-2023
Published Date: Nov-2022
Published Date: Jul-2020
